BACKGROUND: Local delivery of temozolomide (TMZ) through polymers is superior to oral
administration in a rodent glioma model. OBJECTIVE: We hypothesized that the observed …

Purpose Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent
augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized …

Glioblastoma multiforme (GBM) has few clinically approved therapeutic regimens. One of
these therapeutic options includes placing biodegradable wafers releasing BCNU …

We conducted a study to determine the dose-limiting toxicity of an extended dosing
schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1, 3-bis (2 …

Temozolomide, a methylating agent with clinical activity against brain tumors, demonstrated
excellent antitumor activity following po administration to athymic mice bearing human brain …

Object. Mitoxantrone is a drug with potent in vitro activity against malignant brain tumor cell
lines; however, its effectiveness as a systemic agent has been hampered by poor central …

Introduction We have completed in vivo safety and efficacy studies of the use of a novel drug
delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the …

Object Over the past several years, there has been increasing interest in combining
angiogenesis inhibitors with radiotherapy and temozolomide chemotherapy in the treatment …

Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical
models. We report final data from a prospective, multi-institutional study of BCNU wafers and …

Objective Diffuse intrinsic brainstem gliomas are considered to be inoperable. We report our
initial experience of temozolomide (TMZ) administration into brainstem by intracerebral (ic) …